Solaxa and Alvogen enter into license agreement for the development and commercialization of SLX-100
Bethesda, MD and Morristown, NJ, February 23, 2026 — Alvogen, a US-based wholly owned subsidiary of Lotus Pharmaceutical Co., Ltd. (TWSE: […]
Bethesda, MD and Morristown, NJ, February 23, 2026 — Alvogen, a US-based wholly owned subsidiary of Lotus Pharmaceutical Co., Ltd. (TWSE: […]
Solaxa Announces Phase 3 Clinical Trial for Spinocerebellar Ataxia Type 27B Bethesda, MD — March 28, 2025 – Solaxa Inc.,
Solaxa Inc. Announces FDA Clearance of IND Application for SLX-100 Bethesda, MD; January 6, 2024 – Solaxa Inc. announces today
Solaxa Inc. Collaborates with National Ataxia Foundation Bethesda, MD and Minneapolis, MN; September 25, 2024 – On International Ataxia Awareness
Solaxa Inc. Appoints Kerry Clem as Chief Commercial Officer Bethesda, MD; August 19, 2024 – Solaxa Inc. announces that Kerry
U.S. Food and Drug Administration Grants Orphan Drug Designation to Solaxa Inc. Bethesda, MD; July 26, 2024 – Solaxa Inc.
TEDCO Announces SSBCI Investment in Solaxa Inc. Maryland-based biopharmaceutical company receives funding from TEDCO’s Venture Funds COLUMBIA, Md., (July 23,
The Maryland Tech Council (MTC), the largest technology and life sciences trade association in the state, today announced the winners
Rockville, Maryland – September 13, 2023 – BioHealth Innovation, Inc. (BHI), a leading regional innovation intermediary, is thrilled to announce
Researchers at Penn State College of Medicine and Penn State Health Milton S. Hershey Medical Center are leading a clinical trial to evaluate whether